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See Article, pages 583–588The paper by Kokudo et al. [1] in this issue of the Journal of Hepa-
tology timely shakes up the BCLC guidelines for the management
of hepatocellular carcinoma (HCC), raised by certain as absolute
dogma, despite the proponents of these guidelines themselves
as shown by the successive modiﬁcations they regularly propose.
The ‘‘Kokudos’’ (son and father) and co-workers analyse here a
retrospective series of 187 consecutive liver resections for HCC
extending to the hepatic veins. Precisely, the study includes
153 patients with microscopic invasion of the hepatic veins, by
deﬁnition unknown before surgery, 21 with macroscopic major
hepatic vein invasions, and 13 with tumour thrombus into the
inferior vena cava. These 3 subgroups represent 10.0%, 1.3%,
and 0.9%, respectively, of all consecutive HCC (1525 cases) oper-
ated during a 17 years period (1994–2011) at one of the most
prestigious Japanese liver surgery tertiary centres. The main
interesting subgroup concerns patients with macroscopic tumour
thrombus in the main hepatic veins or the vena cava known
before the decision to proceed for surgery (2.2% of operated
HCC). Excellent results could be achieved for this highly selected
subset of severe patients (38.2% with cirrhosis, 14.7% with portal
hypertension) with advanced disease (88.2% with combined por-
tal vein tumour thrombus and 26.5% with P3 tumours): the
90 days mortality rate was 5% and the median survival time
was 3.95 years! Multivariate analysis revealed tumour thrombus
in the vena cava and R1/R2 resection as risk factors for the overall
survival.
These surgeons-authors must be commended for their pug-
nacity and their willingness to share this experience in a journal
of hepatology, i.e., the eponym ‘‘Journal of Hepatology’’. The latter
point is important. Indeed in our numerous discussions at multi-
disciplinary team meetings with our colleagues and hepatologist
friends, all will acknowledge that the latter write, read, and quote
almost exclusively papers from the literature of their specialtyJournal of Hepatology 20
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In other terms, daily, hepatologists and liver surgeons have a dia-
logue of deaf relying on an evidently-biased analysis of the so-
called evidence-based medicine. Of course for a hepatologist
the evidence level of the study by Kokudo et al. is low: What
about the control group? Maybe the patients reported here are
simply harvesting low progressing tumours with a spontaneous
fair survival? . . . However, if the prospective randomised study
comparing resection vs. sorafenib the reference treatment in this
setting of BCLC C patients is ever done, its results will probably
not be applicable to the real life for many well-known reasons.
This means that we eagerly await new methodological tools
maybe such as big health care data analysis or propensity-score
methods to answer to the question with a higher level of evi-
dence. An individualised prognostic score model might be one
solution.
While submitting this point of view, I will take the opportu-
nity to share some additional comments.
Since the Okuda classiﬁcation reported in 1984, more than 10
classiﬁcations of HCC have been reported including the CLIP
(1998), GRETCH and BCLC (1999), CUPI and sTNM (2002), JIS
(2003), Tokyo (2005), AJCC/UICC 7th ed (2010), Taipe (2010).
The absence of even one common criteria to all these classiﬁca-
tions is noteworthy as well as the absence of any classiﬁcation
regrouping all prognostic factors: the quest of the Holy Grail
remains opened, not mentioning the impact of tumour and
peri-tumoral genetics and epigenetics maybe that remain to be
implemented in these models. The BCLC has been endorsed by
the AASLD and the EASL, is widely used in Europe and North
America but is not in Asia. Finally these guidelines are based on
a 15 years old study and drew its conclusion from 77 patients
resected for HCC. The main caveat of all guidelines is that they
target the longest possible survival following surgery for the ideal
candidates. Beyond the deﬁnition of palliative care (a total of 37
English and 26 German deﬁnitions were identiﬁed in a system-
atic review) it would be interesting to have assessment of func-
tional symptoms before resection such as fatigue, pain and
their fate after surgery, and of the quality of life of resected
patients compared to those receiving sorafenib. The rigidity, of
BCLC management algorithm, co-substantial to any guidelines,
should be relaxed by surgical side paths for selected subsets of14 vol. 61 j 462–463
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patients and even for individual patients, achieving better sur-
vival compared to the reference treatment, namely TACE or
radioembolisation for BCLC B and sorafenib for BCLC C patients.
As an example, we can compare 2 patients with the same diagno-
sis of HCC. Both are BCLC C for portal vein tumour thrombus. The
ﬁrst patient is 74 years old, asymptomatic and has a body mass
index of 35 kg/m2 but sarcopenia measured on CT scan. The other
patient is a 54-year old woman with a body mass index of 21 kg/
m2 and no sarcopenia but severe right upper abdominal pain due
to intra-tumoral haemorrhage. The same medical standards in
terms of oncology, surgery, and anaesthesiology should be
applied in these 2 cases, but obviously in the ﬁrst case it is more
difﬁcult to propose resection compared to the second one.
The above-mentioned side paths might beneﬁt from neo-
adjuvant and adjuvant treatments including the optimisation of
the nutritional status, the control of portal hypertension, the
downsizing-downstaging of the tumour burden, and the virosup-
pression of hepatitis. All this to allow surgery for more patients
with portal hypertension, multiple tumors, portal and/or HV
tumour thrombus. As well, the possibility of re-hepatectomy
and liver transplantation (as a bridge or as a salvage procedure)
should be included in the decision process.
This emphasises besides the obvious impacts of hospital and
surgeon volume on the outcome, the utmost importance to man-
age patients with potentially resectable HCC in highly specialised
centres able (1) to evaluate and optimise the patient status and
particularly his nutrition, (2) to offer all available treatments to
obviate the choice of treatment bias, (3) to master multimodality
management including systemic and intra-arterial treatments,
(4) to evaluate the underlying liver parenchyma beyond the Child
Turcotte and MELD classiﬁcations such as ICG clearance test and
scintigraphic assessment of liver function, (5) to optimise the
future remnant liver by portal vein embolisation, (6) to resect
with both minimum bleeding and minimum ischemia-reperfu-
sion minimum injury using techniques and approach both onco-
logical such as anterior approach and mini invasive such as
laparoscopic and laparoscopic robot assisted maybe in the future.
In practice, the surgical approach should be determined on aJournal of Hepatology 201patient-by-patient basis according to the individual risk and fol-
lowing the ‘‘3 rules – 3 objectives’’ of liver surgery. The 3 rules are:
(1) adapt the resection to the disease and not to the surgeon’s
skills; (2) spare parenchymal liver to leave sufﬁcient remnant
functional liver and to anticipate the potential need for re-hepa-
tectomy or transplantation; and (3) balance haemorrhage with its
short- and long-term prognostic impacts on the one hand and
vascular clamping with subsequent I/R injury on the other. The
3 objectives are: (1) decrease morbidity and mortality rates; (2)
improve long-term survival; and (3) increase the number of
resectable patients.
In the ﬁeld of HCC and under the former guidance of M. Mak-
uuchi, the Tokyo group ‘‘performed yesterday the surgery of
today and performs today the surgery of the edge of tomorrow’’.
Our multidisciplinary team meetings are allowed to cut the Gor-
dian knot of the aporetic dilemma: individualised treatment on
one hand vs. guidelines and evidence based medicine on the
other hand might be reconciled. The right of experts is to set
the rules (not too simple to remain true, not too complex to be
applicable), the duty of the same experts is to break the rules
to propose in the ﬁeld of liver surgery for HCC the equivalent of
the metro-ticket model for liver transplantation for the same dis-
ease. If we keep strictly obeying the same rules, the obtained
results will remain the same: up to 1 million deaths yearly due
to HCC worldwide.Conﬂict of interest
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